Hydropothecary awarded Best New Cannabis Product at inaugural Canadian Cannabis Awards

TORONTO, ON–(Marketwired – December 01, 2017) – The Hydropothecary Corporation (“THCX” or the “Company”) (TSX VENTURE: THCX) was awarded two prestigious awards for Best New Cannabis Product last night at the inaugural annual Canadian Cannabis Awards gala.

Hydropothecary took first place for its innovative Decarb, a ready to consume activated and edible cannabis powder. Decarb offers a range of options, from micro-dosing to high potency, giving clients flexibility and convenience.

Elixir, Canada’s first and only peppermint medical cannabis oil sublingual mist, earned third place. This highly innovative product is a further innovation in the Company’s easy to use line.

The awards were held at a gala event at The Carlu in Toronto.

The Hydropothecary was amongst more than 800 guests, including licensed producers, industry representatives and members of the investment community present at the awards.

“We are pleased to accept these awards on behalf of the entire Hydropothecary team. While this is a welcome recognition of our mandate to create excellence in service and product innovation, it is also a reflection of the hard work and vision of our team and their collective determination to continuously set new benchmarks in the industry,” said Adam Miron, Hydropothecary’s Chief Brand Officer and Co-founder.

Hydropothecary, the only licensed producer headquartered in Quebec, currently has 20 products available. The company recently announced a 250,000 sq. ft. expansion, expected to increase its annual production of dried product to 25,000kg.

About The Hydropothecary Corporation

The Hydropothecary Corporation is an authorized licensed producer and distributor of medical cannabis licensed by Health Canada under the Access to Cannabis for Medical Purposes Regulations (Canada). Hydropothecary provides naturally grown and rigorously tested medical cannabis of uncompromising quality. Hydropothecary’s branding, cannabis product offering, patient service standards and product pricing are consistent with Hydropothecary’s positioning as a premium brand for a legal source for medical cannabis within this new marketplace. In addition to medical cannabis production and sales, Hydropothecary explores various research and development opportunities for cannabinoid extracts, drugs and combinatory chemistry. In addition, the company is investigating the development and patenting of novel technologies related to medical cannabis, as well as the import and export of medical cannabis.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


For Investor Relations Inquiries:

Jennifer Smith
Manager of Financial Reporting and Investor Relations
1-866-438-THCX (8429)

For Media Inquiries:

Julie Beun
Publicist and Media Relations


Adam Miron